WW International Q3 revenue falls 10.8%, narrows 2025 guidance

Reuters11-06
WW International Q3 revenue falls 10.8%, narrows 2025 guidance

Overview

  • WW International Q3 revenue declined 10.8% yr/yr

  • Clinical Subscription Revenue grew 35% yr/yr, reflecting strong retention

  • Company narrows 2025 guidance to higher end for revenue and adjusted EBITDA

Outlook

  • Company narrows 2025 revenue guidance to $695 mln - $700 mln

  • Company narrows 2025 adjusted EBITDA guidance to $145 mln - $150 mln

Result Drivers

  • CLINICAL REVENUE GROWTH - Clinical Subscription Revenue increased 35% yr/yr due to strong retention of members using compounded semaglutide

  • DEBT REDUCTION - Co reduced total debt by over 70% post-restructuring, strengthening balance sheet

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

$172 mln

Press Release: ID:nGNXbL53gc

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment